
Oncology NEWS International
- Oncology NEWS International Vol 16 No 11
- Volume 16
- Issue 11
Phase II trials planned for oral methylnaltrexone for chronic pain
Phase II trials planned for oral methylnaltrexone for chronic pain
COLLEGEVILLE, PennsylvaniaWyeth Pharmaceuticals and Progenics plan to initiate two 4-week phase II clinical trials to evaluate daily dosing of oral methylnaltrexone in patients with chronic, nonmalignant pain who are experiencing opioid-induced constipation (OIC). An NDA for the subcutaneous formulation has been filed with FDA for the treatment of OIC in the end-of-life setting.
Articles in this issue
over 18 years ago
MT103, BiTE antibody, enters phase II testing for ALLover 18 years ago
Sides dig in as ESA policy debate heats upover 18 years ago
Ixempra gets ok for resistant breast cancerover 18 years ago
ASCO adds Oncotype DX to marker guidelineover 18 years ago
Dr. Norton hopes to weed 'molecular' tumor gardenover 18 years ago
Accelerated approval for Tasignaover 18 years ago
Oxidative stress inducer ups survival in advanced melanomaover 18 years ago
FDA removes partial hold on Telcyta clinical developmentover 18 years ago
Should all HER2+ pts receive adjuvant trastuzumab?over 18 years ago
R-CHOP is standard of care for advanced DLBCL patientsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.




































